Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

Patient perspectives: Tiffany Peterson

Tiffany Peterson (also known as Tiffany and Lupus) shares what it is like to be a patient with Lupus and how pharma can better work with patients such as her. Frustrated with the lack of information she received after receiving her diagnosis of Lupus, Tiffany Peterson didn’t want other patients to…

Articles

Perspectives on CME: part 4 – the impact of technology on CM...

In the fourth part of our interview series with Lawrence Sherman we learn how technology has shaped CME and where Lawrence gets his inspiration from in his work. In this interview series with CME expert Lawrence Sherman we’ve learned how CME can be of real value to the learner, in addition to...

Articles

Tunnah’s musings: Syrum - saving the world or saving pharma?

Paul Tunnah’s latest musings neatly coincides with the beta launch of Boehringer’s new Facebook game Syrum, as he asks John Pugh what it might do for pharma. It’s probably fair to say that the words ‘pharma’ and ‘glitz’ do not often go hand in hand. However, Boehringer Ingelheim’s John Pugh certainly managed to inject …

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access